ZIOPTAN Drug Patent Profile
✉ Email this page to a colleague
When do Zioptan patents expire, and when can generic versions of Zioptan launch?
Zioptan is a drug marketed by Thea Pharma and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.
This drug has eighty-one patent family members in twenty-six countries.
The generic ingredient in ZIOPTAN is tafluprost. There are three drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the tafluprost profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Zioptan
A generic version of ZIOPTAN was approved as tafluprost by MICRO LABS on August 19th, 2019.
Summary for ZIOPTAN
International Patents: | 81 |
US Patents: | 2 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 2 |
Raw Ingredient (Bulk) Api Vendors: | 56 |
Patent Applications: | 533 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for ZIOPTAN |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for ZIOPTAN |
What excipients (inactive ingredients) are in ZIOPTAN? | ZIOPTAN excipients list |
DailyMed Link: | ZIOPTAN at DailyMed |
Pharmacology for ZIOPTAN
Drug Class | Prostaglandin Analog |
Mechanism of Action | Prostaglandin Receptor Agonists |
Physiological Effect | Increased Prostaglandin Activity |
Anatomical Therapeutic Chemical (ATC) Classes for ZIOPTAN
Paragraph IV (Patent) Challenges for ZIOPTAN
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
ZIOPTAN | Ophthalmic Solution | tafluprost | 0.0015% | 202514 | 2 | 2016-02-10 |
US Patents and Regulatory Information for ZIOPTAN
ZIOPTAN is protected by two US patents.
Patents protecting ZIOPTAN
Method and composition for treating ocular hypertension and glaucoma
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION
Method and composition for treating ocular hypertension and glaucoma
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Thea Pharma | ZIOPTAN | tafluprost | SOLUTION/DROPS;OPHTHALMIC | 202514-001 | Feb 10, 2012 | AT | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||
Thea Pharma | ZIOPTAN | tafluprost | SOLUTION/DROPS;OPHTHALMIC | 202514-001 | Feb 10, 2012 | AT | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ZIOPTAN
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Thea Pharma | ZIOPTAN | tafluprost | SOLUTION/DROPS;OPHTHALMIC | 202514-001 | Feb 10, 2012 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for ZIOPTAN
When does loss-of-exclusivity occur for ZIOPTAN?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Argentina
Patent: 1937
Estimated Expiration: ⤷ Sign Up
Patent: 0961
Estimated Expiration: ⤷ Sign Up
Australia
Patent: 09252210
Estimated Expiration: ⤷ Sign Up
Brazil
Patent: 0913109
Estimated Expiration: ⤷ Sign Up
Canada
Patent: 24194
Estimated Expiration: ⤷ Sign Up
Patent: 65185
Estimated Expiration: ⤷ Sign Up
China
Patent: 2083413
Estimated Expiration: ⤷ Sign Up
Croatia
Patent: 0140979
Estimated Expiration: ⤷ Sign Up
Patent: 0170769
Estimated Expiration: ⤷ Sign Up
Patent: 0200998
Estimated Expiration: ⤷ Sign Up
Patent: 0220361
Estimated Expiration: ⤷ Sign Up
Cyprus
Patent: 15565
Estimated Expiration: ⤷ Sign Up
Patent: 20351
Estimated Expiration: ⤷ Sign Up
Denmark
Patent: 06977
Estimated Expiration: ⤷ Sign Up
Patent: 72249
Estimated Expiration: ⤷ Sign Up
Patent: 05334
Estimated Expiration: ⤷ Sign Up
Patent: 14877
Estimated Expiration: ⤷ Sign Up
Eurasian Patent Organization
Patent: 3661
Estimated Expiration: ⤷ Sign Up
Patent: 1071413
Estimated Expiration: ⤷ Sign Up
European Patent Office
Patent: 27638
Estimated Expiration: ⤷ Sign Up
Patent: 06977
Estimated Expiration: ⤷ Sign Up
Patent: 72249
Estimated Expiration: ⤷ Sign Up
Patent: 05334
Estimated Expiration: ⤷ Sign Up
Patent: 14877
Estimated Expiration: ⤷ Sign Up
Patent: 35656
Estimated Expiration: ⤷ Sign Up
Patent: 89446
Estimated Expiration: ⤷ Sign Up
Georgia, Republic of
Patent: 0156220
Estimated Expiration: ⤷ Sign Up
Hungary
Patent: 33103
Estimated Expiration: ⤷ Sign Up
Patent: 49923
Estimated Expiration: ⤷ Sign Up
Patent: 58079
Estimated Expiration: ⤷ Sign Up
Japan
Patent: 48317
Estimated Expiration: ⤷ Sign Up
Patent: 56868
Estimated Expiration: ⤷ Sign Up
Patent: 49992
Estimated Expiration: ⤷ Sign Up
Patent: 89789
Estimated Expiration: ⤷ Sign Up
Patent: 65584
Estimated Expiration: ⤷ Sign Up
Patent: 11521943
Estimated Expiration: ⤷ Sign Up
Patent: 14133765
Estimated Expiration: ⤷ Sign Up
Patent: 16065095
Estimated Expiration: ⤷ Sign Up
Patent: 17178957
Estimated Expiration: ⤷ Sign Up
Patent: 18154656
Estimated Expiration: ⤷ Sign Up
Patent: 20073574
Estimated Expiration: ⤷ Sign Up
Patent: 21120412
Estimated Expiration: ⤷ Sign Up
Patent: 23085558
Estimated Expiration: ⤷ Sign Up
Jordan
Patent: 39
Estimated Expiration: ⤷ Sign Up
Lithuania
Patent: 72249
Estimated Expiration: ⤷ Sign Up
Patent: 05334
Estimated Expiration: ⤷ Sign Up
Patent: 14877
Estimated Expiration: ⤷ Sign Up
Malaysia
Patent: 9463
Estimated Expiration: ⤷ Sign Up
Mexico
Patent: 10012987
Estimated Expiration: ⤷ Sign Up
Poland
Patent: 06977
Estimated Expiration: ⤷ Sign Up
Patent: 72249
Estimated Expiration: ⤷ Sign Up
Patent: 05334
Estimated Expiration: ⤷ Sign Up
Patent: 14877
Estimated Expiration: ⤷ Sign Up
Portugal
Patent: 06977
Estimated Expiration: ⤷ Sign Up
Patent: 72249
Estimated Expiration: ⤷ Sign Up
Patent: 05334
Estimated Expiration: ⤷ Sign Up
Patent: 14877
Estimated Expiration: ⤷ Sign Up
Singapore
Patent: 1628
Estimated Expiration: ⤷ Sign Up
Slovenia
Patent: 06977
Estimated Expiration: ⤷ Sign Up
Patent: 72249
Estimated Expiration: ⤷ Sign Up
Patent: 05334
Estimated Expiration: ⤷ Sign Up
Patent: 14877
Estimated Expiration: ⤷ Sign Up
South Korea
Patent: 1650006
Estimated Expiration: ⤷ Sign Up
Patent: 1820816
Estimated Expiration: ⤷ Sign Up
Patent: 1988642
Estimated Expiration: ⤷ Sign Up
Patent: 2114401
Estimated Expiration: ⤷ Sign Up
Patent: 2246598
Estimated Expiration: ⤷ Sign Up
Patent: 110011707
Estimated Expiration: ⤷ Sign Up
Patent: 160102319
Estimated Expiration: ⤷ Sign Up
Patent: 180008905
Estimated Expiration: ⤷ Sign Up
Patent: 190067272
Estimated Expiration: ⤷ Sign Up
Patent: 200057801
Estimated Expiration: ⤷ Sign Up
Spain
Patent: 95316
Estimated Expiration: ⤷ Sign Up
Patent: 27837
Estimated Expiration: ⤷ Sign Up
Patent: 08050
Estimated Expiration: ⤷ Sign Up
Patent: 07982
Estimated Expiration: ⤷ Sign Up
Taiwan
Patent: 32202
Estimated Expiration: ⤷ Sign Up
Patent: 1000104
Estimated Expiration: ⤷ Sign Up
Ukraine
Patent: 2257
Estimated Expiration: ⤷ Sign Up
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering ZIOPTAN around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Poland | 3714877 | ⤷ Sign Up | |
European Patent Office | 3714877 | PROCÉDÉ ET COMPOSITION POUR LE TRAITEMENT DE L'HYPERTENSION OCULAIRE ET DU GLAUCOME (METHOD AND COMPOSITION FOR TREATING OCULAR HYPERTENSION AND GLAUCOMA) | ⤷ Sign Up |
Austria | 225770 | ⤷ Sign Up | |
Spain | 2808050 | ⤷ Sign Up | |
South Korea | 20160102319 | 고안압증과 녹내장의 치료 방법 및 조성물 (METHOD AND COMPOSITION FOR TREATING OCULAR HYPERTENSION AND GLAUCOMA) | ⤷ Sign Up |
Croatia | P20200998 | ⤷ Sign Up | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for ZIOPTAN
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0850926 | 11C0020 | France | ⤷ Sign Up | PRODUCT NAME: TAFLUPROST; REGISTRATION NO/DATE IN FRANCE: CIS:6 000 728 O DU 20110328; REGISTRATION NO/DATE AT EEC: 43230 DU 20080430 |
0850926 | SPC/GB09/005 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: TAFLUPROST OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: DK 43230 20080430; UK PL 16058/0011-0001 20081017 |
0850926 | CA 2008 00041 | Denmark | ⤷ Sign Up | |
0850926 | SPC013/2011 | Ireland | ⤷ Sign Up | SPC013/2011: 20110808, EXPIRES: 20221221 |
0850926 | 339 | Finland | ⤷ Sign Up | |
0850926 | 91943 | Luxembourg | ⤷ Sign Up | 91943, EXPIRES: 20221222 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |